BMO Capital Initiates Coverage of BioMarin Pharmaceutical (BMRN) with Market Perform

On January 30, 2023, BMO Capital initiated coverage of BioMarin Pharmaceutical with a Market Perform recommendation.

Analyst Price Forecast Suggests 7.20% Upside

As of January 31, 2023, the average one-year price target for BioMarin Pharmaceutical is $122.96. The forecasts range from a low of $83.83 to a high of $210.00. The average price target represents an increase of 7.20% from its latest reported closing price of $114.70.

The projected annual revenue for BioMarin Pharmaceutical is $2,613MM, an increase of 30.11%. The projected annual EPS is $1.47, an increase of 222.58%.

What are large shareholders doing?

Primecap Management holds 17,625,505 shares representing…

Read more…

Request a Call Back

Contact Info